Explore all subjects

The Expertise Imperative and Compliance Technology
Access to a diverse array of specialized expert inputs drives superior decisions in every organizational context: within corporations, by investors and consultancies, and within nonprofits. When decision makers are confident of their decision inputs, they can respond more quickly and creatively to challenges and opportunities.Learn more about GLG's Compliance Framework


This page may include content provided by Council Members, your access to which is subject to the Terms of Use.
Find Out More

GLG News by HIV Specialists (EU)

July 28, 2008
Bigger concerns about Abacavir than HLA testing
By a GLG Expert Contributor
Analysis of: F.D.A. Urges Genetic Test Before Giving AIDS Drug (www.nytimes.com)
The HLAB5701 test  is inexpensive and uncomplicated to perform  It reduces risk of the hypersenitivity reaction.  Two recent studies have raised  concerns about abacavir. -ACTG 5202 study has indicated that in persons with high viral loads epzicom (the main brand of abacavir)...
March 26, 2008
Impressive results in competitive environment
By a GLG Expert Contributor
Analysis of: Ardea Biosciences Reports Positive Phase 2a Results for Lead HIV Candidate, RDEA806, Demonstrating up to 2.0 Log Reduction in Plasma Viral Load (www.pipelinereview.com)
Impressive 7 day antiviral effects Potential for QD naive and BD experienced approaches Potential for coformulations Revised formulation moving into next phase of testing No critical safety issues in volunteers or patients Metabolit may be anti-gout agent
February 11, 2008
A new NNRTI strong,safe and respectful of other similar drugs next use
By a GLG Expert Contributor
Analysis of: Promising phase I/II data in HIV with once-daily NNRTI from Idenix (www.pipelinereview.com)
HIV therapy must be the strongest and the most safe therapy ; NNRTI are the key drugs for this kind of therapy. When you,doctor,begin a  naive HIV therapy, you must think that your patient should be treated for a very long time , maybe for a whole life period ; it'simportant...
December 20, 2007
Very Good News For HIV Infected Individuals. Sandro Vento, MD. Azienda Ospedaliera di Cosenza, Italy
By a GLG Expert Contributor
Analysis of: European Commission Approves ATRIPLA(R) (efavirenz 600 mg/emtricitabine 200 mg/tenofovir disoproxil fumarate 300 mg), the First Once-Daily Single Tablet Regimen for Virologically Suppressed Adults With HIV-1 Infection (www.pipelinereview.com)
Atripla is a fixed combination in a single pill of three excellent antiretroviral drugs with very good pharmacokinetics profile and fairly good tolerability. It will have a considerable impact on compliance as it can be taken once daily. If compliance will be as good as predictable, the chances that...
July 5, 2007
Small delay for first CCR5 antagonsit
By a GLG Expert Contributor
Analysis of: Pfizer Receives Approvable Letter From FDA For Maraviroc (www.pipelinereview.com)
While ideally Maraviroc would now be approved the requests from the FDA do not require new clinical trials. The main issues relate to the failings of other drugs in this class Aplaviroc (Ono/GSK) discontinued for hepatotoxicity and questions over malignancies with Vicriviroc (Schering-Plough). Data...

Page : 11 to 5 of 5

Analytics


Generated at 2009-01-07T13:00:17.563